I hope you're right. Although I understand the market's right to sell first, and ask questions later. Add the Nexavar phenomenon to Avastin's woes, and you have a very powerful cocktail that must be stirred and not shaken. The directors have done the only reasonable thing for people in their position, and that is to line their pockets before this train comes right off its tracks. A pile of negative clinical evidence is piling up on Progen, and the next bit of news could be the straw that broke the camel's back. Look out for a sharp and decisive correction to the downside.
PGL Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held